Production of chondroitin in metabolically engineered E. coli

Metabolic Engineering

Volumn 27, Issue , 2015, Pages 92-100

  He, Wenqin ^a   Fu, Li ^a   Li, Guoyun ^a   Andrew Jones, J ^a   Linhardt, Robert J ^a,b   Koffas, Mattheos ^a,b  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b Research Rensselaer Polytechnic Institute   (United States)

Author keywords

Capsular polysaccharide; Chondroitin; Escherichia coli; Glycosaminoglycan; Metabolic engineering

Indexed keywords

ANIMALS; CHAINS; DISSOLVED OXYGEN; ESCHERICHIA COLI; GENE EXPRESSION; HYDROGELS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; SULFUR COMPOUNDS;

CAPSULAR POLYSACCHARIDES; CHONDROITIN; CHONDROITIN SULFATES; FED-BATCH BIOREACTORS; GLYCOSAMINOGLYCANS; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; REGULATORY SIGNALS; SHAKE-FLASK EXPERIMENTS;

METABOLIC ENGINEERING;

BACTERIAL POLYSACCHARIDE; CHONDROITIN; CHONDROITIN SULFATE; DISACCHARIDE; DISSOLVED OXYGEN; CHONDROITIN SULFATES;

ARTICLE; BACTERIAL STRAIN; CARBOHYDRATE SYNTHESIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ESCHERICHIA COLI; FED BATCH FERMENTATION; FED BATCH REACTOR; GENE EXPRESSION; GLYCOSAMINOGLYCAN METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC ENGINEERING; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SULFATION; BIOSYNTHESIS; GENES, BACTERIAL; GENETICS; METABOLISM;

ESCHERICHIA COLI;

CHONDROITIN SULFATES; ESCHERICHIA COLI; GENE EXPRESSION; GENES, BACTERIAL; METABOLIC ENGINEERING;

EID: 84914129027     PISSN: 10967176     EISSN: 10967184     Source Type: Journal    
DOI: 10.1016/j.ymben.2014.11.003     Document Type: Article

References (40)

1. Andreishcheva E.N., Vann W.F. Escherichia coli BL21(DE3) chromosome contains a group II capsular gene cluster. Gene 2006, 384:113-119. 10.1016/j.gene.2006.07.020.
2. Antonio, T., Immacolata, B., Daly, S., (inventors), Gnosis S.P.A., (assignee), 2013. Biotechnological production of Chondroitin. US Patent 20120010399. (issued 2013, Dec 17).
3. Avci F.Y., Kasper D.L. How bacterial carbohydrates influence the adaptive immune system. Annu. Rev. Immunol. 2010, 28:107-130. 10.1146/annurev-immunol-030409-101159.
4. Belcher C., Yaqub R., Fawthrop F., Bayliss M., Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann. Rheum. Dis. 1997, 56:299-307.
5. Bhan N., Xu P., Koffas M.A.G. Pathway and protein engineering approaches to produce novel and commodity small molecules. Curr. Opin. Biotechnol. 2013, 24:1137-1143. 10.1016/j.copbio.2013.02.019.
6. Bitter, T., Muir, H.M., 1962. A modified uronic acid carbazole reaction 334, 330-334.
7. Cimini D., De Rosa M., Carlino E., Ruggiero A., Schiraldi C. Homologous overexpression of rfaH in E.coli K4 improves the production of chondroitin-like capsular polysaccharide. Microb. Cell Fact. 2013, 12:46. 10.1186/1475-2859-12-46.
8. Cimini D., De Rosa M., Viggiani A., Restaino O.F., Carlino E., Schiraldi C. Improved fructosylated chondroitin production by kfoC overexpression in E. coli K4. J. Biotechnol. 2010, 150:324-331. 10.1016/j.jbiotec.2010.09.954.
9. Cimini D., Restaino O.F., Catapano A., De Rosa M., Schiraldi C. Production of capsular polysaccharide from Escherichia coli K4 for biotechnological applications. Appl. Microbiol. Biotechnol. 2010, 85:1779-1787. 10.1007/s00253-009-2261-8.
10. Cirino P.C., Chin J.W., Ingram L.O. Engineering Escherichia coli for xylitol production from glucose-xylose mixtures. Biotechnol. Bioeng. 2006, 95:1167-1176. 10.1002/bit.21082.
11. Cress B.F., Englaender J.A., He W., Kasper D., Linhardt R.J., Koffas M.A. Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol. Rev. 2014, 1-38. 10.1111/1574-6976.12056.
12. Cress B.F., Greene Z.R., Linhardt R.J., Koffas M.A.G. Draft genome sequence of Escherichia coli strain ATCC 23502 (Serovar O5:K4:H4). Genome Announc. 2013, 1:e0004613. 10.1128/genomeA.00046-13.
13. DeAngelis P.L., Gunay N.S., Toida T., Mao W., Linhardt R.J. Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohydr. Res. 2002, 337:1547-1552.
14. Doherty, D.H., Weaver, C.A., Minamisawa, T., Miyamoto, k., (inventors) Martek Bioscience Corp., Seikagaku Corp. (assignee), 2014. Compositions and methods for bacterial production of chondroitin. US Patent 20110244520, (issued 2014 April 15).
15. Fu L., Li G., Yang B., Onishi A., Li L., Sun P., Zhang F., Linhardt R.J. Structural characterization of pharmaceutical heparins prepared from different animal tissues. J. Pharm. Sci. 2013, 102:1447-1457. 10.1002/jps.23501.
16. Johnson J.R. Virulence factors in Escherichia coli urinary tract infection. Clin. Microbiol. Rev. 1991, 4:80-128.
17. Krahulec J., Krahulcová J., Medová M., Velebny V. Influence of KfoG on capsular polysaccharide structure in Escherichia coli K4 strain. Mol. Biotechnol. 2005, 30:129-134. 10.1385/MB:30:2:129.
18. Liu J., Yang A., Liu J., Ding X., Liu L., Shi Z. KfoE encodes a fructosyltransferase involved in capsular polysaccharide biosynthesis in Escherichia coli K4. Biotechnol. Lett. 2014, 36:1469-1477. 10.1007/s10529-014-1502-9.
19. Manzoni M., Bergomi S., Molinari F., Cavazzoni V. Production and purification of an extracellularly produced K4 polysaccharide from Escherichia coli. Biotechnol. Lett. 1996, 18:383-386. 10.1007/BF00143456.
20. McCarty M.F., Russell A.L., Seed M.P. Sulfated glycosaminoglycans and glucosamine may synergize in promoting synovial hyaluronic acid synthesis. Med. Hypotheses 2000, 54:798-802. 10.1054/mehy.1999.0954.
21. Michel, B., Brühlmann, P., Stucky, G., Uebelhart, D., 2002. Chondro-protection through chondroitin 4 & 6 sulphate (Condrosulf®): the Zurich study., In: Proceedings of the IBSA Satellite Symposium Held at the Annual European Congress of Rheumatology (EULAR), Stockholm.
22. Moxon E.R., Kroll J. The role of bacterial polysaccharide as virulence factors. Curr. Top. Microbiol. Immunol. 1990, 150:65-85.
23. Neidhardt F.C., Bloch P.L., Smith D.F. Culture medium for enterobacteria. J. Bacteriol. 1974, 119:736-747.
24. Ninomiya T., Sugiura N., Tawada A., Sugimoto K., Watanabe H., Kimata K. Molecular cloning and characterization of chondroitin polymerase from Escherichia coli strain K4. J. Biol. Chem. 2002, 277:21567-21575. 10.1074/jbc.M201719200.
25. Osawa T., Sugiura N., Shimada H., Hirooka R., Tsuji A., Shirakawa T., Fukuyama K., Kimura M., Kimata K., Kakuta Y. Crystal structure of chondroitin polymerase from Escherichia coli K4. Biochem. Biophys. Res. Commun. 2009, 378:10-14. 10.1016/j.bbrc.2008.08.121.
26. Restaino O.F., Cimini D., Rosa M.De, Catapano A., Schiraldi C., Rosa M.De High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor[U+202F]: a step towards improvement of chondroitin precursor production. Microb. Cell Fact. 2011, 10:1-11. 10.1186/1475-2859-10-10.
27. Rodriguez M.L., Jann B., Jann K. Structure and serological characteristics of the capsular K4 antigen of Escherichia coli O5:K4:H4, a fructose-containing polysaccharide with a chondroitin backbone. Eur. J. Biochem. 1988, 177:117-124.
28. Sakai S., Akiyama H., Sato Y., Yoshioka Y., Linhardt R.J., Goda Y., Maitani T., Toida T. Chondroitin sulfate intake inhibits the IgE-mediated allergic response by down-regulating Th2 responses in mice. J. Biol. Chem. 2006, 281:19872-19880. 10.1074/jbc.M509058200.
29. Schiraldi C., Cimini D., De Rosa M. Production of chondroitin sulfate and chondroitin. Appl. Microbiol. Biotechnol. 2010, 87:1209-1220. 10.1007/s00253-010-2677-1.
30. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthr. Cartil. 2003, 11:433-441. 10.1016/S1063-4584(03)00051-7.
31. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J. Pharm. Pharmacol. 2009, 61:1271-1280. 10.1211/jpp.61.10.0002.
32. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu. Rev. Biochem. 2006, 75:39-68. 10.1146/annurev.biochem.75.103004.142545.
33. Wiles T.J., Kulesus R.R., Mulvey M.a Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp. Mol. Pathol. 2008, 85:11-19. 10.1016/j.yexmp.2008.03.007.
34. Wu Q., Yang A., Zou W., Duan Z., Liu J., Chen J., Liu L. Transcriptional engineering of Escherichia coli K4 for fructosylated chondroitin production. Biotechnol. Prog. 2013, 29:1140-1149. 10.1002/btpr.1777.
35. Xu P., Gu Q., Wang W., Wong L., Bower A.G.W., Collins C.H., Koffas M.a G. Modular optimization of multi-gene pathways for fatty acids production in E. coli. Nat. Commun. 2013, 4:1409. 10.1038/ncomms2425.
36. Xu P., Vansiri A., Bhan N., Koffas M.a.G. ePathBrick: a synthetic biology platform for engineering metabolic pathways in E. coli. ACS Synth. Biol. 2012, 1:256-266. 10.1021/sb300016b.
37. Yang B., Chang Y., Weyers A.M., Sterner E., Linhardt R.J. Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J. Chromatogr. A 2012, 1225:91-98. 10.1016/j.chroma.2011.12.063.
38. Zanfardino A., Restaino O.F., Notomista E., Cimini D., Schiraldi C., De Rosa M., De Felice M., Varcamonti M. Isolation of an Escherichia coli K4 kfoC mutant over-producing capsular chondroitin. Microb. Cell Fact. 2010, 9:34. 10.1186/1475-2859-9-34.
39. Zhang C., Liu L., Teng L., Chen J., Liu J., Li J., Du G., Chen J. Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor. Metab. Eng. 2012, 14:521-527. 10.1016/j.ymben.2012.06.005.
40. Zoppetti, G., Oreste, P., 2004. Process for the preparation of chondroitin sulfates from k4 polysaccharide and obtained products.